News Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Market Closed - Nyse Other stock markets 04:00:02 2024-05-08 pm EDT			Pre-market 09:29:04 am
14.81 ^USD	-0.60%		14.74	-0.44%

May. 06	Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	MT
May. 06	Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	May. 06	MT
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	May. 06	MT
Bausch Health Announces First Quarter 2024 Results	May. 03	AQ
RBC Capital Reviews Bausch + Lomb's Q1 Results	May. 02	MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	May. 02	MT
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	May. 01	MT
Bausch + Lomb Q1 Loss Widens, Revenue Increases	May. 01	MT
Transcript : Bausch + Lomb Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	May. 01	MT
Bausch + Lomb: Q1 Earnings Snapshot	May. 01	AQ
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	May. 01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	May. 01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	May. 01	MT
Bausch + Lomb Announces First-Quarter 2024 Results	May. 01	BU
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting	Apr. 29	BU
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	Apr. 25	MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Summary

Filters